- Home
- WINT vs PALI Comparison
WINT vs PALI Comparison
Compare WINT & PALI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WINT
- PALI
- Stock Information
- Founded
- WINT 1992
- PALI 1996
- Country
- WINT United States
- PALI United States
- Employees
- WINT N/A
- PALI N/A
- Industry
- WINT Biotechnology: Biological Products (No Diagnostic Substances)
- PALI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- WINT Health Care
- PALI Health Care
- Exchange
- WINT Nasdaq
- PALI Nasdaq
- Market Cap
- WINT 3.6M
- PALI 3.2M
- IPO Year
- WINT 1995
- PALI N/A
- Fundamental
- Price
- WINT $0.57
- PALI $0.70
- Analyst Decision
- WINT Hold
- PALI Strong Buy
- Analyst Count
- WINT 1
- PALI 2
- Target Price
- WINT $350.00
- PALI $12.00
- AVG Volume (30 Days)
- WINT 264.4K
- PALI 410.9K
- Earning Date
- WINT 05-16-2025
- PALI 05-12-2025
- Dividend Yield
- WINT N/A
- PALI N/A
- EPS Growth
- WINT N/A
- PALI N/A
- EPS
- WINT N/A
- PALI N/A
- Revenue
- WINT N/A
- PALI N/A
- Revenue This Year
- WINT N/A
- PALI N/A
- Revenue Next Year
- WINT N/A
- PALI N/A
- P/E Ratio
- WINT N/A
- PALI N/A
- Revenue Growth
- WINT N/A
- PALI N/A
- 52 Week Low
- WINT $0.55
- PALI $0.60
- 52 Week High
- WINT $737.44
- PALI $5.15
- Technical
- Relative Strength Index (RSI)
- WINT 26.04
- PALI 44.12
- Support Level
- WINT $0.67
- PALI $0.67
- Resistance Level
- WINT $0.81
- PALI $0.86
- Average True Range (ATR)
- WINT 0.06
- PALI 0.06
- MACD
- WINT 0.01
- PALI -0.01
- Stochastic Oscillator
- WINT 5.24
- PALI 22.24
About WINT Windtree Therapeutics Inc.
Windtree Therapeutics Inc is a biotechnology company focused on advancing early and late-stage therapies for critical conditions and diseases. Its portfolio of product candidates includes istaroxime, a Phase 2 candidate with sarco endoplasmic reticulum Ca2+ -ATPase 2a, or SERCA2a, activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure, rostafuroxin for the treatment of hypertension in patients with a specific genetic profile, and a preclinical atypical protein kinase C iota, or aPKCi, inhibitor, being developed for potential application in rare and broad oncology indications. It operates in one operating segment, which is the research and development of products focused on cardiovascular disease.
About PALI Palisade Bio Inc.
Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.